Clinical Trials Logo

Filter by:
NCT ID: NCT06160882 Recruiting - Amputation Clinical Trials

Powered Prosthesis for Use With TF Osseointegration Recipients

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate functional mobility, control, and user satisfaction from persons who have an amputation above the knee and have received osseo-integration (OI) and targeted muscle reinnervation (TMR) surgery, while walking with a powered knee and ankle prosthesis.

NCT ID: NCT06160791 Not yet recruiting - Clinical trials for Hemophagocytic Lymphohistiocytoses

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests the effects of ruxolitinib in combination with a de-intensified HLH-94 drug regimen has on patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH), a disorder caused by dysregulated immune responses (that is, immune responses that are too strong and cause inflammatory damage to normal tissues). The therapy used for HLH decreases the activity of the immune system. Ruxolitinib is a type of drug called a kinase inhibitor. It works by blocking the signals that cause inflammatory cells to multiply. De-intensified HLH-94 is a treatment regimen that includes 4 weeks of dexamethasone with the dose being decreased each week, and up to 4 weeks of etoposide. This combination is commonly used to treat HLH. Dexamethasone is a steroid medication that works by fighting inflammation. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill cancer cells and is used to kill the types of white blood cells in HLH that are attacking the body. Giving ruxolitinib in combination with a de-intensified HLH-94 drug regimen may reduce toxic exposure to therapy while maintaining efficacy in patients with HLH.

NCT ID: NCT06160752 Recruiting - Solid Tumor Clinical Trials

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

SURF201
Start date: November 22, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.

NCT ID: NCT06160700 Terminated - Cancer Clinical Trials

Serial Testing To Assess Cognitive Function In Cancer

Start date: April 20, 2022
Phase:
Study type: Observational

The purpose of this study is to examine the effects of immunotherapy on cognitive function of cancer patients and follow them clinically over a period of six months with the Montreal cognitive assessment (MoCA) to assess changes in cognition.

NCT ID: NCT06160648 Not yet recruiting - Neck Pain Clinical Trials

The Comparative Effectiveness of Interventions in People With Neck Pain Who Exhibit Directional Preference

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare physical therapy treatments in people with neck pain. The main aim is to compare the short-term effectiveness of physical therapy treatment for neck pain as delivered through Mechanical Diagnosis and Therapy (MDT) as compared to the Cervical Spine Clinical Practice Guidelines (CPGs) in patients with neck pain. Participants will be randomly allocated to receive treatment according to MDT or CPG guidelines. Researchers will compare outcomes between the two groups over 1 year.

NCT ID: NCT06160427 Recruiting - Shoulder Pain Clinical Trials

Connective Tissue Matrix for Rotator Cuff Tendinopathy

Start date: December 4, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine if the effectiveness of a single injection of CTM Boost in the treatment of patients with rotator cuff tendinopathy (RCT) is as effective as a single injection of platelet rich plasma (PRP) in reducing the symptoms of RCT.

NCT ID: NCT06160349 Enrolling by invitation - Infections Clinical Trials

EnCoRe MoMS:Engaging Communities to Reduce Morbidity From Maternal Sepsis

Start date: July 20, 2023
Phase:
Study type: Observational

Sepsis is the second leading cause of maternal death in the U.S. For racial and ethnic minoritized birthing people, especially those who are Black, living in poverty, and from underserved communities, labor and postpartum are particularly vulnerable risk periods. The goal of this multi-center, multidisciplinary observational study is to establish a novel maternal care continuity model to reduce sepsis- related death and disability and increase maternal health equity.

NCT ID: NCT06160310 Recruiting - Clinical trials for Tuberous Sclerosis Complex

Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.

NCT ID: NCT06160284 Not yet recruiting - Opioid Use Disorder Clinical Trials

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Start date: July 2024
Phase: Phase 1
Study type: Interventional

This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the [11C]-UCB-J radiotracer while inpatient.

NCT ID: NCT06160258 Not yet recruiting - Health Behavior Clinical Trials

Impact of Convenience on Whole Grain Consumption

WG
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

Intact whole grains (such as quinoa, buckwheat, and barley) contain all 3 parts of the kernel (bran, germ, and endosperm) compared to processed grains where the bran and germ layers have been removed. Intact whole grains have a higher nutritional value but are under consumed in the diet of most adults. In this proposed pilot study, 42 participants will be recruited to study the impact of convenience on intake of intact whole grains by comparing consumption of intact whole grains that are offered in a convenient pre-cooked ready-to-eat form compared to traditional bulk dried form that requires a more prolonged preparation and cooking time. The ready-to-eat meals will be processed using WSU microwave technologies to ensure food safety. All intact whole grains (ready-to-eat or dried) will be provided to participants, who will prepare and consume the grains at home over a period of 4 weeks. Type and volume of whole grain consumed will be monitored daily via REDCap survey, which will allow the investigators to see if adults are more likely to meet daily recommended intakes of whole grain servings when offered in a convenient form.